Megakaryocyte — the platelet factory whose loss causes the bruising that brings these children in, and which also holds stem cells still

A megakaryocyte is the largest cell in the bone marrow, up to 100 micrometres across, with a single enormous lobed nucleus carrying many copies of the genome — it divides its DNA repeatedly without dividing the cell, a process called endomitosis, reaching 16N, 32N or more. It then extends long cytoplasmic ribbons called proplatelets through the wall of a marrow blood vessel, and the shear of flowing blood snaps them into platelets. One megakaryocyte yields on the order of a few thousand platelets.

Platelets are the cells that stop bleeding. When their number falls, small vessels leak: the result is petechiae (pinpoint red spots that do not blanch), easy bruising, nosebleeds and gum bleeding. In infant leukaemia the marrow fills with blasts and megakaryocytes are displaced, so thrombocytopenia is among the earliest and most visible signs. This graph records the presentation in concept-bruising-petechiae-thrombocytopenia; this entry records the cell.

The niche literature long assumed that every cell regulating HSCs was non-haematopoietic. Two 2014 papers showed otherwise, and they matter here because the state they regulate is the one this graph blames for residual disease.

Three-dimensional whole-mount imaging placed endogenous HSCs adjacent to megakaryocytes non-randomly. Selective in vivo depletion of megakaryocytes caused specific loss of HSC quiescence and a marked expansion of functional HSCs. Megakaryocytes were the bone-marrow source of CXCL4/PF4; injecting CXCL4 reduced HSC number by increasing their quiescence, while Cxcl4-null mice had more HSCs and more HSC proliferation 1.

The parallel study found the same phenomenon with a different mediator and added a switch. Megakaryocyte ablation activated quiescent HSCs; megakaryocytes express TGF-beta1 at higher levels than other stromal niche cells, ablation reduced active TGF-beta1 and nuclear pSMAD2/3 in HSCs, and conditional deletion of Tgfb1 in megakaryocytes increased HSC activation. But after chemotherapeutic challenge megakaryocyte ablation caused a severe defect in HSC expansion, because under stress FGF1 signalling from megakaryocytes transiently dominates over TGF-beta inhibition to drive HSC expansion 2.

That second result is the interesting one for this disease. Chemotherapy both destroys megakaryocytes and changes what the surviving ones signal. If leukaemic stem-cell quiescence is regulated by the same axis, then treatment itself remodels the niche that decides whether residual cells stay dormant or re-enter cycle — and the direction of that remodelling flips between homeostasis and post-injury regeneration.

Acute myeloid leukaemia with megakaryocytic differentiation (AMkL) accounts for 4-15 percent of newly diagnosed childhood AML and is uncommon in adults. In a Children's Oncology Group central-review series of 107 non-Down-syndrome paediatric AMkL cases, fusions were identified in the majority and KMT2A rearrangements made up 7 percent; those cases, along with CBFA2T3::GLIS2, had worse outcomes than other AMkL 3.

No KMT2A-rearranged megakaryocytic cell line exists in the standard DepMap panel — indeed none of the 11 rearranged lines there has erythroid or megakaryocytic character at all. So this is a clinically real, prognostically adverse subgroup with no laboratory model, which makes it structurally invisible to preclinical work. See cell-type-mep.